Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04230746
Other study ID # IRB00224835
Secondary ID
Status Withdrawn
Phase Early Phase 1
First received
Last updated
Start date October 2023
Est. completion date February 2026

Study information

Verified date October 2021
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Planning to study urine microbiota at baseline and after administration of bactrim antibiotics in healthy volunteers. Will intermittently collect voided urine specimens for 16 s DNA analysis over a period of 6 months after 2 weeks of bactrim or placebo.


Description:

Urinary tract infections (UTI) are the most common type of human bacterial disease, prompting more than 10 million physician office visits annually at a healthcare cost of over $1 billion dollars. Treatment of UTI is typically empiric or culture-driven antibiotics which are associated with ever increasing bacterial resistance. Over the last decade, The Human Microbiome Project has established that even 'culture-negative' urine represents a diverse ecosystem of bacteria. Despite broad use of antibiotics to cure disease for the past 90 years, the broader impact of antibiotics on typical flora are not well understood. Antibiotics are also commonly used as prophylaxis for surgical procedures in the urinary tract altering patient outcomes in unforeseen ways. Despite widespread utilization of antibiotics, the longitudinal impact on the dynamic intravesical environment remains completely unknown. Dysbiosis in the microbiome has been suggested as a causative agent in a wide range of disease: arthritis, metabolic disorders, neurologic disease, inflammatory bowel conditions, and cancer. Yet there remains a fundamental knowledge gap regarding the short and long-term effect of antibiotics on microbiota communities. Specifically within the urinary tract, variance in baseline commensal organisms have been associated with interstitial cystitis, overactive bladder, frequent symptomatic urinary tract infection and potentially cancer development. The study of microbiota reveal pathways and mechanisms that play important roles in immunological response and health but studies typically are limited to the gut. To address this knowledge gap, the investigators plan a placebo controlled randomized trial to test the longitudinal impact of 10 days of trimethoprim-sulfamethoxazole on the urinary microbiome in healthy adults. Data collection for individual participants will persist for a period of 6 months. The investigators hypothesize antibiotic administration contributes to a rise in bacterial resistance and directly leads to urine microbiome dysbiosis. The investigators further hypothesize the urinary microbiome does not return to baseline, with loss of certain bacteria permanent during the study period. While the investigators' study is groundbreaking and novel, the feasibility of the investigators' experimental plan has been previously demonstrated in the study of the salivary and gut microbiome. Ultimately the investigators anticipate even a single course of antibiotic treatment may increase the risk of bacterial resistance and lead to long-lasting shifts in the urinary microbiome. If confirmed, this knowledge will directly influence clinical decision making in antibiotic selection, duration, and utility.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 2026
Est. primary completion date February 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Exclusion Criteria: - Diagnosed or suspected urinary tract infection in prior 6 months - Treated with antibiotics for any reason in prior 6 months - Allergy to sulfa - Under 18 - Pregnant or planning to become pregnant in the next 12 months by self report (as is the clinical standard for prescribing this medication for suspected or proven UTI treatment) - Use indwelling or intermittent urinary hardware or implant such as supra-pubic tube or catheter - Neurogenic bladder - Baseline renal insufficiency - Glucose-6-phosphate dehydrogenase deficiency - Taking angiotensin converting enzyme - Angiotensin receptor blocker - Nursing - HIV/AIDS - On Immunosuppressant drugs - On Chemotherapy/Immunotherapy - Liver dysfunction - On the following medications: DOFETILIDE, METHENAMINE & LEVOMETHADYL; WARFARIN & Methotrexate; GEMIFLOXACIN, DIGOXIN, PYRIMETHAMINE, CLASS IA ANTIARRHYTHMIC AGENTS (Quinidine, procainamide, disopyramide), TRICYCLIC ANTIDEPRESSANTS (amitriptyline, desipramine, doxepin, Imipramine, nortriptyline, amoxapine, clomipramine, maprotiline, trimipramine, and protriptyline), LEUCOVORIN CALCIUM.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bactrim DS 800Mg-160Mg Tablet
To study effect on urinary microbiome
Placebo oral tablet
To study effect on urinary microbiome

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Johns Hopkins University

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Microbiome flora number of organisms Analysis of 16S rRNA gene amplicon data to determine number of varied organisms (genus and species). At Baseline, Day 2, Day 5, Day 10, Day 30, and Day 180 of study
Primary Change in Microbiome flora percentage distribution of organisms Analysis of 16S rRNA gene amplicon data to determine the percent distribution of organisms (microbiologic genus and species). At Baseline, Day 2, Day 5, Day 10, Day 30, and Day 180 of study
See also
  Status Clinical Trial Phase
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Recruiting NCT05502380 - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery Phase 3
Withdrawn NCT04462133 - Optimal Tailored Treatment for H. Pylori Infection N/A
Completed NCT03535324 - Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT) N/A
Recruiting NCT05950984 - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Active, not recruiting NCT03865706 - Inulin for Infections in the Intensive Care Unit Phase 2
Not yet recruiting NCT06028217 - Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
Completed NCT05391035 - The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
Recruiting NCT05224401 - Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs Phase 3
Not yet recruiting NCT03855709 - Antibiotic-resistant Bacterial Infection of Hepatic Patients
Terminated NCT03535272 - Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea Phase 3
Recruiting NCT05902299 - Evaluation of the Impact of the Modification of Antibiotic Susceptibility Testing on Antibiotic Prescriptions
Recruiting NCT05293483 - The Impact of Covid-19 Hospital Care on the Prevalence of MDRO in Indonesia
Recruiting NCT05561504 - Helicobacter Pylori Local Prevalence and Antibiotic Resistance
Recruiting NCT03606031 - Digestive Microbiota Transplant
Completed NCT01573195 - Merck IISP Stewardship Grant for Antibiotic Best Practices Phase 4
Not yet recruiting NCT03857295 - Infections Following NeuroSurgery (INS)
Not yet recruiting NCT03180983 - Antibiotic Use in French Nursing Home N/A